The pharmacological rationale for targeting IL-17 in certain asthma phenotypes is legitimated by its role in exacerbating severity characteristics; it reduces corticosteroids sensitivity [17] and induces hyperresponsiveness [18]. The gene discussed is IL17A; the disease is asthma.